Skip to Content

Pulmozyme Side Effects

Generic Name: dornase alfa

Note: This page contains side effects data for the generic drug dornase alfa. It is possible that some of the dosage forms included below may not apply to the brand name Pulmozyme.

In Summary

Common side effects of Pulmozyme include: transient skin rash and voice disorder. Other side effects include: laryngitis. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to dornase alfa: inhalation solution

As well as its needed effects, dornase alfa (the active ingredient contained in Pulmozyme) may cause unwanted side effects that require medical attention.

Major Side Effects

If any of the following side effects occur while taking dornase alfa, check with your doctor immediately:

More common:
  • Body aches or pain
  • chest pain
  • congestion
  • cough
  • dryness or soreness of the throat
  • fever
  • hoarseness
  • runny nose
  • tender, swollen glands in the neck
  • trouble breathing
  • trouble swallowing
  • voice changes

Minor Side Effects

Some dornase alfa side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:

More common:
  • Acid or sour stomach
  • belching
  • heartburn
  • indigestion
  • rash
  • sneezing
  • stomach discomfort, upset, or pain
  • stuffy nose
Less common:
  • Burning, dry, or itching eyes
  • discharge or excessive tearing
  • redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid

For Healthcare Professionals

Applies to dornase alfa: inhalation solution


Dornase alfa (the active ingredient contained in Pulmozyme) has been generally well tolerated. Dose ranging studies employing daily dosages as high as 40 mg revealed no significant adverse effects. The most common adverse reactions have been respiratory in nature and included pharyngitis (36% to 40% versus 33% with placebo, n=968), voice alteration or hoarseness (12% to 16% versus 7%), laryngitis (3% to 4% versus 1%), dyspnea and increase in cough. Rash has also occurred frequently (10% to 12% versus 7%).[Ref]

Many of these adverse reactions have been difficult to distinguish from symptoms of the underlying disease. Hoarseness and pharyngitis have been shown to be dose-related in one study. The hoarseness was transient and regressed after a 3 week period. Withdrawal rates in clinical trials have been similar between active and placebo groups.[Ref]


Cardiovascular side effects have included chest pain, which has been reported in 18% to 21% of patients receiving dornase alfa (the active ingredient contained in Pulmozyme) versus 16% with placebo.[Ref]


Ocular side effects have included conjunctivitis which has been reported in 4% to 5% of patients receiving dornase alfa (the active ingredient contained in Pulmozyme) versus 2% with placebo.[Ref]


Hypersensitivity side effects have included a small percentage of patients who developed serum antibodies to the drug, but no anaphylaxis or severe allergic reactions have been reported. The clinical relevance of the rhDNase antibodies is presently unknown. No immunoglobulin E antibodies have been detected. exposed to the drug during clinical trials[Ref]


Special face masks are not needed for caregivers involved with the administration of dornase alfa (the active ingredient contained in Pulmozyme) Studies have shown that the passive airborne exposure is well below the clinical dose during administration and nondetectable 15 to 45 minutes after treatment.[Ref]


1. "Product Information. Pulmozyme (dornase alfa)." Genentech, South San Francisco, CA.

2. Bryson HM, Sorkin EM "Dornase alfa. A review of its pharmacological properties and therapeutic potential in cystic fibrosis." Drugs 48 (1994): 894-906

3. Fuchs HJ, Borowitz DS, Christiansen DH, et al. "Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis." N Engl J Med 331 (1994): 637-42

4. Witt DM, Anderson L "Dornase alfa: a new option in the management of cystic fibrosis." Pharmacotherapy 16 (1996): 40-8

It is possible that some side effects of Pulmozyme may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.